Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

An acceptable safety profile and early evidence of clinical activity was observed with ziftomenib plus standard regimens in select patients with AML.

Related Keywords

Samer Zeidan ,Division Of Hematologic Malignancies ,Hematologic Malignancies ,Hematology Early Therapeutics Research ,Yale Cancer Center ,Ziftomenib ,Phase 1 2 Komet 007 Trial ,Nct04067336 ,Aml ,Acute Myeloid Leukemia ,Npm1 Mutant And Kmt2a Rearranged ,Npm1 Mutant And Kmt2a Rearranged Aml ,Venclexta ,Vidaza ,Azacitidine ,Venetoclax ,Cytarabine And Daunorubicin 7 3 ,